NCM
CGTX icon

Neumann Capital Management’s Cognition Therapeutics CGTX Stock Holding History

Neumann Capital Management’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,382
Closed -$48.1K – 92
2023
Q3 		$48.1K Hold
33,382
– – 0.02% 93
2023
Q2 		$61.1K Hold
33,382
– – 0.03% 92
2023
Q1 		$66.1K Hold
33,382
– – 0.03% 90
2022
Q4 		$70.1K Buy
+33,382
New +$67.4K 0.03% 89

Other funds holding CGTX

Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Neumann Capital Management's CGTX Position: Q4 2023 in Review

Neumann Capital Management sold out of Cognition Therapeutics (CGTX) in Q4 2023, closing a stake of 33,382 shares — an estimated $48.1K sold.

Neumann Capital Management first reported a position in CGTX in Q4 2022 and held it in 4 quarters. The position peaked at $70.1K in Q4 2022. 37 funds tracked by Wall St. Rank hold CGTX as of Q4 2023.

  • Neumann Capital Management reported no remaining Cognition Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Neumann Capital Management sold 33,382 Cognition Therapeutics shares in Q4 2023, an estimated $48.1K.
  • Neumann Capital Management first reported a position in Cognition Therapeutics in Q4 2022 and held it in 4 quarters.
  • Neumann Capital Management's Cognition Therapeutics position peaked at $70.1K in Q4 2022.
  • 37 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q4 2023.

Based on Neumann Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.